AbClon Inc
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more
AbClon Inc (174900) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.075x
Based on the latest financial reports, AbClon Inc (174900) has a cash flow conversion efficiency ratio of -0.075x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.18 Billion) by net assets (₩29.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AbClon Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how AbClon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AbClon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbClon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jingjin Environmental Protection Co Ltd
SHG:603279
|
0.049x |
|
Googol Technology Co Ltd Class A
SHE:301510
|
N/A |
|
Shanghai Shyndec Pharmaceutical Co Ltd
SHG:600420
|
0.031x |
|
Orient Semiconductor Electronics Ltd
TW:2329
|
0.006x |
|
Taiwan Secom Co Ltd
TW:9917
|
0.077x |
|
Paramount Resources Ltd.
PINK:PRMRF
|
0.016x |
|
MUANGTHAI CAPITAL PCL-NVDR
BK:MTC-R
|
-0.030x |
|
Bursa Malaysia Bhd Ord
PINK:BSMAF
|
0.108x |
Annual Cash Flow Conversion Efficiency for AbClon Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of AbClon Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩29.41 Billion | ₩-14.39 Billion | -0.490x | -40.56% |
| 2023-12-31 | ₩27.23 Billion | ₩-9.48 Billion | -0.348x | -70.15% |
| 2022-12-31 | ₩36.60 Billion | ₩-7.49 Billion | -0.205x | +54.15% |
| 2021-12-31 | ₩19.36 Billion | ₩-8.64 Billion | -0.446x | -131.82% |
| 2020-12-31 | ₩29.33 Billion | ₩-5.65 Billion | -0.193x | -1414.49% |
| 2019-12-31 | ₩35.38 Billion | ₩-449.88 Million | -0.013x | -106.40% |
| 2018-12-31 | ₩18.70 Billion | ₩3.71 Billion | 0.199x | +409.96% |
| 2017-12-31 | ₩17.39 Billion | ₩-1.11 Billion | -0.064x | -274.68% |
| 2016-12-31 | ₩11.98 Billion | ₩-204.92 Million | -0.017x | +89.66% |
| 2015-12-31 | ₩13.31 Billion | ₩-2.20 Billion | -0.165x | -- |